Live from Open Targets Platform, fetched 2026-11-12 00:34 UTC. Every row links to its source record.

ARHGEF40 Rho guanine nucleotide exchange factor 40

ENSG00000165801 · protein coding · Open Targets profile

Acts as a guanine nucleotide exchange factor (GEF) for RHOA and RHOC (PubMed:15107133, PubMed:26823019). Promotes actin stress fiber formation, force-induced stress fiber reinforcement and organization of KRT8/KRT18 networks via activation of RHOA/ROCK signaling, which is mediated by N-terminus KRT18 binding (PubMed:26823019, PubMed:30929300). Regulates the formation or maintenance of properly elongated morphology of epithelial tubules, via mediation of the organization and orientation of KRT18 filaments (By similarity). Promotes RHOA-dependent, cell-cell contact mediated reorientation of endothelial cells and their actin stress fibers in response to mechanotransduction (PubMed:25795300). Positively regulates hemidesmosome formation via acting as a linker protein that anchors keratin filaments to hemidesmosomes (PubMed:29672603). Also required for JUP localization at cell-cell adhesion junctions (PubMed:26823019). {ECO:0000250|UniProtKB:A0A8I3PMN2, ECO:0000269|PubMed:15107133, ECO:0000269|PubMed:25795300, ECO:0000269|PubMed:26823019, ECO:0000269|PubMed:29672603, ECO:0000269|PubMed:30929300}.

In 3 of 7 cancers, the evidence for ARHGEF40 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Antibody: GO CC high conf, Human Protein Atlas loc
PROTAC: Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.5906299948692322 (upper bound 0.6985999941825867). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of ARHGEF40's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of ARHGEF40's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

Drug	Type	Highest stage	Indications	Source records
No drugs or clinical candidates recorded.